Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

Also called NCT02251067

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 165 participants (enrolled count) (from the registry)
Sponsor
Vascular Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT02251067
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02251067. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2017-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
Condition
Diabetic Nephropathy
Intervention (Drug)
VPI-2690B low dose
Intervention (Drug)
VPI-2690B medium dose
Intervention (Drug)
Placebo to match VPI-2690B
Intervention (Drug)
VPI-2690B high dose
Lead sponsor
Vascular Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02251067
Content hash
7ebb4a205ea6a355609ef1c6a21551c987d7b895cb2d02656bd6f1b9433d8443